Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Oncocyte banks on a new kind of liquid biopsy
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Oxford Nanopore, the disruptive unicorn gunning for Illumina
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.